These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 9098917)

  • 1. Antiretroviral therapy: a guide to the most important trials.
    Rutschmann O; Hirschel B
    Schweiz Med Wochenschr; 1997 Mar; 127(11):436-43. PubMed ID: 9098917
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
    Prescrire Int; 2004 Aug; 13(72):144-50. PubMed ID: 15532140
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Antiretroviral treatment in human immunodeficiency virus infection].
    Blum L; Bachmeyer C
    Ann Dermatol Venereol; 1997; 124(9):641-54. PubMed ID: 9739932
    [No Abstract]   [Full Text] [Related]  

  • 4. The 48-week efficacy of once-daily saquinavir/ritonavir in patients with undetectable viral load after 3 years of antiretroviral therapy.
    Cardiello P; Srasuebkul P; Hassink E; Mahanontharit A; Samor T; Ruxrungtham K; Lange J; Cooper D; Phanuphak P
    HIV Med; 2005 Mar; 6(2):122-8. PubMed ID: 15807718
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prospective follow-up of 67 indinavir-experienced human immunodeficiency virus-infected and AIDS patients treated with the ritonavir/saquinavir combination.
    Lallemand F; Adda N; Schneider V; Jacomet C; Salhi Y; Rozenbaum W
    Clin Infect Dis; 1999 May; 28(5):1184-5. PubMed ID: 10452672
    [No Abstract]   [Full Text] [Related]  

  • 6. Efficacy and safety of indinavir/ritonavir 400/100 mg twice daily plus two nucleoside analogues in treatment-naive HIV-1-infected patients with CD4+ T-cell counts <200 cells/mm3: 96-week outcomes.
    Mootsikapun P; Chetchotisakd P; Anunnatsiri S; Boonyaprawit P
    Antivir Ther; 2005; 10(8):911-6. PubMed ID: 16430196
    [TBL] [Abstract][Full Text] [Related]  

  • 7. AIDS therapy with two, three or four agent combinations, applied in short sequences, differing from each other by drug rotation. I. First of two parts: a phase I trial equivalent, concerning five virostatics: AZT, ddI, ddC, acriflavine and an ellipticine analogue.
    Mathé G; Pontiggia P; Orbach-Arbouys S; Triana K; Ambetima N; Morette C; Hallard M; Blanquet D
    Biomed Pharmacother; 1996; 50(5):220-7. PubMed ID: 8949403
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized double-blind trial of the addition of lamivudine or matching placebo to current nucleoside analogue reverse transcriptase inhibitor therapy in HIV-infected children: the PENTA-4 trial. Paediatric European Network for Treatment of AIDS.
    AIDS; 1998 Oct; 12(14):F151-60. PubMed ID: 9792371
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Observational study on the efficacy of the application of two classical regimens of triple antiretroviral therapy].
    Eiros Bouza JM; Ortega Lafont M; Ortiz de Lejarazu R; Bachiller Luque P; de Luis Román DA
    An Med Interna; 2003 May; 20(5):239-42. PubMed ID: 12831297
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A patient's guide to protease inhibitors.
    Elperin A; Sax P
    AIDS Clin Care; 1996 Oct; 8(10):83-4. PubMed ID: 11363988
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New drugs for HIV infection.
    Med Lett Drugs Ther; 1996 Apr; 38(972):35-7. PubMed ID: 8606677
    [TBL] [Abstract][Full Text] [Related]  

  • 12. AVANTI 2. Randomized, double-blind trial to evaluate the efficacy and safety of zidovudine plus lamivudine versus zidovudine plus lamivudine plus indinavir in HIV-infected antiretroviral-naive patients.
    AIDS; 2000 Mar; 14(4):367-74. PubMed ID: 10770538
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ddI and d4T plus protease inhibitors.
    GMHC Treat Issues; 1996 Nov; 10(11):8-9. PubMed ID: 11364012
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Durable HIV-1 suppression with indinavir after failing lamivudine-containing double nucleoside therapy: a randomized controlled trial.
    Foudraine NA; Jurriaans S; Weverling GJ; Burger DM; Hoetelmans RM; Roos MT; Maas J; Miedema F; Reiss P; Portegies P; de Wolf F; Lange JM
    Antivir Ther; 2001 Mar; 6(1):55-62. PubMed ID: 11417762
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of human immunodeficiency virus type 1 drug resistance in children receiving nucleoside analogue reverse-transcriptase inhibitors plus nevirapine, nelfinavir, or ritonavir (Pediatric AIDS Clinical Trials Group 377).
    Eshleman SH; Krogstad P; Jackson JB; Wang YG; Lee S; Wei LJ; Cunningham S; Wantman M; Wiznia A; Johnson G; Nachman S; Palumbo P
    J Infect Dis; 2001 Jun; 183(12):1732-8. PubMed ID: 11372025
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cure or control of HIV/AIDS?
    Collins DO; Sakamoto A
    Med Hypotheses; 1997 Jun; 48(6):489-90. PubMed ID: 9247891
    [No Abstract]   [Full Text] [Related]  

  • 17. Tenofovir: new indication. For first-line antiretroviral therapy: wait and see.
    Prescrire Int; 2004 Oct; 13(73):180-2. PubMed ID: 15499699
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of didanosine and lamivudine both once daily plus indinavir in human immunodeficiency virus-infected patients.
    de Mendoza C; Soriano V; Pérez-Olmeda M; Rodríguez-Rosado R; González-Lahoz J
    J Hum Virol; 2000; 3(6):335-40. PubMed ID: 11100914
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Different outcomes in patients achieving complete or partial viral load suppression on antiretroviral therapy.
    de Mendoza C; Soriano V; Pérez-Olmeda M; Rodés B; Casas E; González-Lahoz J
    J Hum Virol; 1999; 2(6):344-9. PubMed ID: 10774551
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drugs for HIV infection.
    Med Lett Drugs Ther; 1997 Dec; 39(1015):111-6. PubMed ID: 9402928
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.